A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein.

A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein.

Nature communications (2019-09-14)

Aimin Tang, Zhifeng Chen, Kara S Cox, Hua-Poo Su, Cheryl Callahan, Arthur Fridman, Lan Zhang, Sangita B Patel, Pedro J Cejas, Ryan Swoyer, Sinoeun Touch, Michael P Citron, Dhanasekaran Govindarajan, Bin Luo, Michael Eddins, John C Reid, Stephen M Soisson, Jennifer Galli, Dai Wang, Zhiyun Wen, Gwendolyn J Heidecker, Danilo R Casimiro, Daniel J DiStefano, Kalpit A Vora

PMID31515478

ABSTRACT

Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant mortality under six months of age worldwide; therefore, the prevention of RSV infection in all infants represents a significant unmet medical need. Here we report the isolation of a potent and broadly neutralizing RSV monoclonal antibody derived from a human memory B-cell. This antibody, RB1, is equipotent on RSV A and B subtypes, potently neutralizes a diverse panel of clinical isolates in vitro and demonstrates in vivo protection. It binds to a highly conserved epitope in antigenic site IV of the RSV fusion glycoprotein. RB1 is the parental antibody to MK-1654 which is currently in clinical development for the prevention of RSV infection in infants.

MATERIALS

Product Number

Brand

Product Description

A2055

Sigma-Aldrich

ACCUSPIN^™ Tubes Sterile, 50 mL Capacity, radiation sterilized tube fitted with a high density polyethylene barrier

MAB80124

Sigma-Aldrich

Anti-Human Metapneumovirus Antibody, clone 132, clone 132, Chemicon^®, from mouse